Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”

Group 1 - Bristol-Myers Squibb Company (NYSE:BMY) is experiencing renewed interest from investors, particularly in the context of a macroeconomic rally, as highlighted by Jim Cramer [1] - The stock saw a significant increase of 5.6% following news related to a drug trial for agitated Alzheimer's patients, despite the trial not being a formal approval or a well-executed study [1] - The company is recognized for its development and sale of medicines targeting various conditions, including cancer, heart, immune, and brain disorders, with notable products like Eliquis, Opdivo, Revlimid, and Orencia [2] Group 2 - While Bristol-Myers Squibb is acknowledged for its investment potential, there are suggestions that certain AI stocks may offer greater upside potential and lower downside risk [3]